Stock MXCT MAXCYTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News MaxCyte, Inc.

Equities

MXCT

US57777K1060

Market Closed - London S.E.
Other stock markets
 11:35:14 2024-04-25 am EDT 		5-day change 1st Jan Change
295 GBX -3.28% Intraday chart for MaxCyte, Inc. -5.75% -16.31%
Apr. 02 MaxCyte inks deal with Be Bio; Orcadian firms farmout AN
Apr. 02 MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
GL
MaxCyte, Inc. - Exercise of options and PDMR dealing
AQ
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B cell Medicines
AQ
MaxCyte inks deal with Be Bio; Orcadian firms farmout
AN
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
GL
MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines
CI
MaxCyte, Inc. - Grant of Options, RSUs and PSUs and PDMR Dealing
AQ
BTIG Adjusts Price Target on MaxCyte to $8 From $10, Maintains Buy Rating
MT
MaxCyte loss widens in 2023 as core revenue declines 25%
AN
North American Morning Briefing : Stock Futures Flat After S&P 500 Hit Record High
DJ
MaxCyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : MaxCyte, Inc., 2023 Earnings Call, Mar 12, 2024
MaxCyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Earnings Flash (MXCT) MAXCYTE Reports Q4 Revenue $15.7M, vs. Street Est of $15.1M
MT
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
GL
MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024
CI
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
AQ
EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit
AN
MaxCyte Reaffirms Fiscal 2023 Revenue Guidance
MT
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MXCT Stock
  4. News MaxCyte, Inc.